Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?

Karaolides T, Skolarikos A, Bourdoumis A, Konandreas A, Mygdalis V, Thanos A, Deliveliotis C.

Urology. 2012 Aug;80(2):354-9. doi: 10.1016/j.urology.2012.03.067.

PMID:
22857752
2.

Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?

Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P.

BJU Int. 2012 Feb;109(4):549-56. doi: 10.1111/j.1464-410X.2011.10374.x. Epub 2011 Jun 28.

3.

HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.

Geavlete B, Jecu M, Multescu R, Georgescu D, Geavlete P.

Urology. 2010 Sep;76(3):664-9. doi: 10.1016/j.urology.2010.02.067. Epub 2010 Jun 8.

PMID:
20627289
5.

Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.

Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D.

Eur Urol. 2014 Nov;66(5):863-71. doi: 10.1016/j.eururo.2014.06.037. Epub 2014 Jul 4. Review.

PMID:
25001887
6.

Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.

Gkritsios P, Hatzimouratidis K, Kazantzidis S, Dimitriadis G, Ioannidis E, Katsikas V.

Int Urol Nephrol. 2014 May;46(5):927-33. doi: 10.1007/s11255-013-0603-z. Epub 2013 Nov 19.

PMID:
24249423
7.

Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.

Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S.

BJU Int. 2011 Oct;108(8 Pt 2):E297-303. doi: 10.1111/j.1464-410X.2011.10090.x. Epub 2011 Mar 17.

8.
9.

Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB.

J Urol. 2010 Nov;184(5):1907-13. doi: 10.1016/j.juro.2010.06.148. Epub 2010 Sep 17.

10.

Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer.

Ray ER, Chatterton K, Thomas K, Khan MS, Chandra A, O'Brien TS.

J Endourol. 2009 Jun;23(6):983-8. doi: 10.1089/end.2008.0642.

PMID:
19441882
11.

A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.

Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ; PC B302/01 Study Group.

J Urol. 2007 Jul;178(1):62-7. Epub 2007 May 11.

PMID:
17499283
12.

Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.

Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M.

J Urol. 2012 Jul;188(1):58-62. doi: 10.1016/j.juro.2012.03.007. Epub 2012 May 12.

13.

Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.

Geavlete B, Multescu R, Georgescu D, Geavlete P.

J Endourol. 2009 Jun;23(6):977-81. doi: 10.1089/end.2008.0574.

PMID:
19473068
14.

Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.

Burger M, Stief CG, Zaak D, Stenzl A, Wieland WF, Jocham D, Otto W, Denzinger S.

Urology. 2009 Dec;74(6):1282-6. doi: 10.1016/j.urology.2009.06.088. Epub 2009 Oct 12.

PMID:
19819538
15.

Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.

Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, Loening SA, Schnorr D.

J Urol. 2005 Dec;174(6):2129-33, discussion 2133.

PMID:
16280742
16.
17.

Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL).

Bader MJ, Stepp H, Beyer W, Pongratz T, Sroka R, Kriegmair M, Zaak D, Welschof M, Tilki D, Stief CG, Waidelich R.

Urol Oncol. 2013 Oct;31(7):1178-83. doi: 10.1016/j.urolonc.2012.02.007. Epub 2012 Mar 21.

PMID:
22440147
18.

Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.

Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Fradet Y, Karl A, Burgués JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D.

Eur Urol. 2013 Nov;64(5):846-54. doi: 10.1016/j.eururo.2013.03.059. Epub 2013 Apr 8. Review.

PMID:
23602406
19.
20.

Supplemental Content

Support Center